Tvardi Therapeutics, an AIM-HI Accelerator Fund portfolio company, has won recognition as one of the ten “Most Promising” companies at the 2020 Texas Life Science Forum. Hosted by BioHouston and the Rice Alliance, the 2020 Texas Life Science Forum is…
Oncoheroes Biosciences, a biotech focused on advancing new therapies for childhood cancer, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate, volasertib, for use in treating pediatric rhabdomyosarcoma and other rare…
Tvardi Therapeutics Inc., a privately held, clinical-stage biopharmaceutical portfolio company of the AIM-HI Accelerator Fund focused on the development of STAT3 inhibitors, announced today over $5 million in non-dilutive grants to support the ongoing validation and clinical development of its…
Oncoheroes Biosciences, currently working on the clinical development of volasertib, a potential new drug for rhabdomyosarcoma patients, is honored to announce the receipt of funding from Super Sam Foundation, a pediatric cancer non-profit. Read more: https://oncoheroes.com/insights-news-1/2020/5/29/oncoheroes-biosciences-and-super-sam-foundation-walking-together-for-the-pediatric-cancer-heroes
Oncoheroes Biosciences, a biotech focused exclusively on advancing new therapies for children with cancer, receives another endorsement from a childhood cancer non-profit. The support received by The Gregory Foundation for Cancer Research will help accelerate the clinical drug development of…
Three Decades of NFCR Basic and Translational Research Funding to Primary Investigator Dr. Yung-Chi Cheng and Project Advances New Systems Biology Paradigm for Cancer Treatment World-First Phase II Multi-Regional Clinical Trial for a Botanical Cancer Drug Candidate ROCKVILLE, MD –…
ROCKVILLE, MD & BOSTON, MA – An AIM-HI Accelerator Fund portfolio company exclusively focused on the development of pediatric cancer therapeutics has garnered recognition and additional funding. Oncoheroes Biosciences Inc. won the Squinto-LePera Award at the Lyfebulb-Helsinn Cancer Innovation Summit…
A drug and drug delivery candidate technology, research into which has been funded by the National Foundation for Cancer Research (NFCR), has recently been approved by the U.S. Food and Drug Administration (FDA) for the initiation of human clinical trials.…
First of Its Kind Investment Competition for Female-Led Cancer-Focused Start-Ups ROCKVILLE, MD – The AIM-HI Accelerator Fund is organizing the first annual Women’s Venture Competition on May 20 in Boston. Applications are being accepted online until April 16 from oncology…
ROCKVILLE, MD – The co-founder and CEO of the AIM-HI Accelerator Fund will chair a panel conversation at an event coinciding with the annual JP Morgan Healthcare Conference. On Sunday, January 12, Sujuan Ba, Ph.D., will lead a morning discussion…
